Literature DB >> 2515542

Inflammatory bowel disease: nutritional implications and treatment.

D B Silk1, J Payne-James.   

Abstract

It is clear that the nutritional state of patients with inflammatory bowel disease is often impaired and that the provision of nutritional support results in an improvement in nutritional state of these patients. Improvement in nutritional status can be achieved as effectively with enteral as with parenteral nutrition. The nutritional support appears to have no primary therapeutic effect in patients with ulcerative colitis. With regard to nutritional support in Crohn's disease, parenteral nutrition should be restricted to use as supportive rather than primary therapy. Available information now seems to suggest that most of the benefits of parenteral nutrition in Crohn's disease are related to improvement in nutritional state rather than as primary therapy, and its use should be restricted to treatments of specific complications of Crohn's disease, such as intestinal obstruction, related to stricture formation or short bowel syndrome following repeated resection. The present available evidence indicates that defined elemental diets may have a primary therapeutic role in the management of first acute attacks of Crohn's disease when there is a need to improve the nutritional status of patients with inflammatory bowel disease as an adjunct to primary drug therapy. Enteral nutrition is as efficacious as parenteral nutrition; moreover, it is safer to administer and more cost-effective.

Entities:  

Mesh:

Year:  1989        PMID: 2515542     DOI: 10.1079/pns19890051

Source DB:  PubMed          Journal:  Proc Nutr Soc        ISSN: 0029-6651            Impact factor:   6.297


  9 in total

1.  The effect of body weight on the severity and clinical course of ulcerative colitis.

Authors:  Denia Stabroth-Akil; Ludger Leifeld; Roland Pfützer; Julia Morgenstern; Wolfgang Kruis
Journal:  Int J Colorectal Dis       Date:  2014-11-14       Impact factor: 2.571

Review 2.  [What is the role of nutrition in Crohn disease? A contribution to the importance of dietary therapy in regional enteritis].

Authors:  E Nagel; H Canzler; R Pichlmayr
Journal:  Langenbecks Arch Chir       Date:  1991

3.  Pellagra complicating Crohn's disease.

Authors:  I Zaki; L Millard
Journal:  Postgrad Med J       Date:  1995-08       Impact factor: 2.401

4.  Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease.

Authors:  K T Park; L Sceats; M Dehghan; A W Trickey; A Wren; J J Wong; R Bensen; B N Limketkai; K Keyashian; C Kin
Journal:  Aliment Pharmacol Ther       Date:  2018-06-07       Impact factor: 8.171

5.  Elevated plasma leptin concentrations in early stages of experimental intestinal inflammation in rats.

Authors:  M Barbier; C Cherbut; A C Aubé; H M Blottière; J P Galmiche
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

6.  Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone.

Authors:  D A Gorard; J B Hunt; J J Payne-James; K R Palmer; R G Rees; M L Clark; M J Farthing; J J Misiewicz; D B Silk
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

7.  Leptin antagonist ameliorates chronic colitis in IL-10⁻/⁻ mice.

Authors:  Udai P Singh; Narendra P Singh; Hongbing Guan; Brandon Busbee; Robert L Price; Dennis D Taub; Manoj K Mishra; Raja Fayad; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Immunobiology       Date:  2013-05-13       Impact factor: 3.144

Review 8.  The emerging role of leptin antagonist as potential therapeutic option for inflammatory bowel disease.

Authors:  Udai P Singh; Narendra P Singh; Hongbing Guan; Brandon Busbee; Robert L Price; Dennis D Taub; Manoj K Mishra; Raja Fayad; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Int Rev Immunol       Date:  2013-07-10       Impact factor: 5.311

9.  Effect of turmeric on colon histology, body weight, ulcer, IL-23, MPO and glutathione in acetic-acid-induced inflammatory bowel disease in rats.

Authors:  Salim M A Bastaki; Mohammed Majed Al Ahmed; Ahmed Al Zaabi; Naheed Amir; Ernest Adeghate
Journal:  BMC Complement Altern Med       Date:  2016-02-23       Impact factor: 3.659

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.